Richard Woessner
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cytokine Signaling Pathways and Interactions, Epigenetics and DNA Methylation, Microtubule and mitosis dynamics, Immune cells in cancer
Most-Cited Works
- Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.(1991)
- → AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer(2015)433 cited
- → STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial(2018)282 cited
- → Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors(2012)184 cited
- → Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma(2012)172 cited
- → STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer(2019)151 cited
- → Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.(1990)127 cited
- → Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade(2020)116 cited
- → Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity(2020)97 cited
- Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.(1990)